[
  {
    "ts": null,
    "headline": "The Bull Case For Pfizer (PFE) Could Change Following New First-Line BRAFTOVI Colorectal Cancer Approval",
    "summary": "On 24 February 2026, Pfizer reported that the U.S. FDA granted full approval for BRAFTOVI (encorafenib) plus cetuximab and fluorouracil-based chemotherapy to treat adults with BRAF V600E-mutant metastatic colorectal cancer, upgrading its prior accelerated approval based on outcomes from the Phase 3 BREAKWATER trial. This decision makes BRAFTOVI the only targeted first-line combination regimen for this specific metastatic colorectal cancer population, underscoring Pfizer’s emphasis on...",
    "url": "https://finnhub.io/api/news?id=7a17d66699f3dbc34466a032efc4ac18c06fca5e0a53941d83c869cc9e35227d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772053817,
      "headline": "The Bull Case For Pfizer (PFE) Could Change Following New First-Line BRAFTOVI Colorectal Cancer Approval",
      "id": 139225196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On 24 February 2026, Pfizer reported that the U.S. FDA granted full approval for BRAFTOVI (encorafenib) plus cetuximab and fluorouracil-based chemotherapy to treat adults with BRAF V600E-mutant metastatic colorectal cancer, upgrading its prior accelerated approval based on outcomes from the Phase 3 BREAKWATER trial. This decision makes BRAFTOVI the only targeted first-line combination regimen for this specific metastatic colorectal cancer population, underscoring Pfizer’s emphasis on...",
      "url": "https://finnhub.io/api/news?id=7a17d66699f3dbc34466a032efc4ac18c06fca5e0a53941d83c869cc9e35227d"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Initiates Coverage of Pfizer (PFE) with Underperform Recommendation",
    "summary": "RBC Capital Initiates Coverage of Pfizer (PFE) with Underperform Recommendation",
    "url": "https://finnhub.io/api/news?id=3ab0a05bc3a5b28e1ff6c5b4ad7c8efcc9ed005aba7af271d280d3c71f60d759",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772049828,
      "headline": "RBC Capital Initiates Coverage of Pfizer (PFE) with Underperform Recommendation",
      "id": 139224409,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3ab0a05bc3a5b28e1ff6c5b4ad7c8efcc9ed005aba7af271d280d3c71f60d759"
    }
  },
  {
    "ts": null,
    "headline": "ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing",
    "summary": "LONDON, February 25, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase strand transfer inhibitor (INSTI) in development for HIV.1 Results show a single-dose injection could maintain drug levels for up to six months. In-vitro data from a separate study demonstrate improved potency and an enhanced resistance",
    "url": "https://finnhub.io/api/news?id=4ce6aa5f56af8722edb795baacff20ce841f124b64210f25f940ba868f6d4377",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772046000,
      "headline": "ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing",
      "id": 139224034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LONDON, February 25, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase strand transfer inhibitor (INSTI) in development for HIV.1 Results show a single-dose injection could maintain drug levels for up to six months. In-vitro data from a separate study demonstrate improved potency and an enhanced resistance",
      "url": "https://finnhub.io/api/news?id=4ce6aa5f56af8722edb795baacff20ce841f124b64210f25f940ba868f6d4377"
    }
  },
  {
    "ts": null,
    "headline": "ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen",
    "summary": "LONDON, February 25, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined with monthly intramuscular (IM) long-acting cabotegravir (CAB LA), maintained viral suppression in",
    "url": "https://finnhub.io/api/news?id=0f931e7b301211d864bbb4cb78748f3e544e1a2d70b53174bb1f0b956ec9492b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772046000,
      "headline": "ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen",
      "id": 139224033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LONDON, February 25, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined with monthly intramuscular (IM) long-acting cabotegravir (CAB LA), maintained viral suppression in",
      "url": "https://finnhub.io/api/news?id=0f931e7b301211d864bbb4cb78748f3e544e1a2d70b53174bb1f0b956ec9492b"
    }
  },
  {
    "ts": null,
    "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
    "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
    "url": "https://finnhub.io/api/news?id=fd179c9bbe20abdd9972864ad70fb56fd3bd3c1f562aeee5619e9286e4076039",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772031440,
      "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
      "id": 139210537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
      "url": "https://finnhub.io/api/news?id=fd179c9bbe20abdd9972864ad70fb56fd3bd3c1f562aeee5619e9286e4076039"
    }
  },
  {
    "ts": null,
    "headline": "Can J&J Sustain Its Double-Digit Oncology Growth Streak?",
    "summary": "JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?",
    "url": "https://finnhub.io/api/news?id=ba45cee31689e9da54a64d074b4fc30860d13dcf0660dec8cbfde6c06856b970",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772027340,
      "headline": "Can J&J Sustain Its Double-Digit Oncology Growth Streak?",
      "id": 139210551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?",
      "url": "https://finnhub.io/api/news?id=ba45cee31689e9da54a64d074b4fc30860d13dcf0660dec8cbfde6c06856b970"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock: Is PFE Underperforming the Healthcare Sector?",
    "summary": "Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects",
    "url": "https://finnhub.io/api/news?id=3aec763cb04db56053be7003d0feb211c1637b8dd15823f541cbc2c5e0e33672",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772025997,
      "headline": "Pfizer Stock: Is PFE Underperforming the Healthcare Sector?",
      "id": 139215591,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects",
      "url": "https://finnhub.io/api/news?id=3aec763cb04db56053be7003d0feb211c1637b8dd15823f541cbc2c5e0e33672"
    }
  },
  {
    "ts": null,
    "headline": "These 4 charts show the scale of Novo Nordisk's woes",
    "summary": "Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.",
    "url": "https://finnhub.io/api/news?id=16985f75739012f9804d2c8eecc059bddaf431662a1b6197fe1e120314a3474f",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771997562,
      "headline": "These 4 charts show the scale of Novo Nordisk's woes",
      "id": 139212445,
      "image": "https://image.cnbcfm.com/api/v1/image/108245068-1766477256303-gettyimages-2228673815-raa-novonord250809_npj4Z.jpeg?v=1768247892&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.",
      "url": "https://finnhub.io/api/news?id=16985f75739012f9804d2c8eecc059bddaf431662a1b6197fe1e120314a3474f"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer (PFE) Offering Value After Mixed Multi Year Share Price Performance",
    "summary": "If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the numbers actually say about the stock. Pfizer's recent share price reflects mixed returns, with a 0.8% decline over the last 7 days, gains of 5.8% over 30 days and 7.8% year to date, and longer term returns of 8.9% over 1 year, a 19.8% decline over 3 years, and 4.0% over 5 years. Recent headlines around Pfizer have focused on the company reshaping its portfolio and...",
    "url": "https://finnhub.io/api/news?id=a4ceb95562e05670ea1562c01c96c5cf341b2f0c91162566f44e426ba6eee091",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771985470,
      "headline": "Is Pfizer (PFE) Offering Value After Mixed Multi Year Share Price Performance",
      "id": 139203816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the numbers actually say about the stock. Pfizer's recent share price reflects mixed returns, with a 0.8% decline over the last 7 days, gains of 5.8% over 30 days and 7.8% year to date, and longer term returns of 8.9% over 1 year, a 19.8% decline over 3 years, and 4.0% over 5 years. Recent headlines around Pfizer have focused on the company reshaping its portfolio and...",
      "url": "https://finnhub.io/api/news?id=a4ceb95562e05670ea1562c01c96c5cf341b2f0c91162566f44e426ba6eee091"
    }
  }
]